Navigation Links
FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
Date:11/15/2010

PHILADELPHIA, Nov. 15, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17.  The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.

"This adolescent indication for Vyvanse is good news for kids in this age group diagnosed with ADHD and their caregivers as it offers an additional treatment option to help them manage their symptoms," said Mike Yasick, Senior Vice President of Shire's ADHD Business.  "The approval of Vyvanse for children and adults – and now for adolescents – underscores Shire's commitment to helping ADHD patients and their families."  

The FDA's approval of Vyvanse in adolescents was based on results from a randomized, double-blind, placebo-controlled, four-week, forced-dose escalation study of adolescents who received one of three Vyvanse doses, 30, 50 and 70 mg/day, or a placebo.  This study was conducted in 314 adolescents aged 13 to 17 who met DSM-IV-TR® criteria for ADHD.  In this study, patients were randomized to a daily morning dose of Vyvanse (30 mg/day, 50 mg/day or 70 mg/day) or placebo for a total of four weeks of treatment.  All subjects receiving Vyvanse were initiated on 30 mg for the first week of treatment. Subjects assigned to the 50 mg and 70 mg dose groups were escalated
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
2. FDA Approves New Indication for Afinitor
3. FDA Approves Teflaro for Bacterial Infections
4. FDA Approves Latuda to Treat Schizophrenia in Adults
5. FDA Approves Additional Medical Indication for Sprycel
6. FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
7. FDA Approves Pradaxa to Prevent Stroke in People With Atrial Fibrillation
8. FDA Approves Botox to Treat Chronic Migraine
9. FDA Approves Injectable Drug to Treat Opioid-Dependent Patients
10. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
11. FDA Approves Combination Contraceptive Containing a Folate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Reportlinker.com announces that a new market research ... Commercial Insight: Antihormonal Cancer Therapies ... sales erosion http://www.reportlinker.com/p0255121/Commercial-Insight-Antihormonal-Cancer-Therapies---Leading-brands-strive-to-minimize-generic-sales-erosion.html ... are a class of drugs used predominantly ...
... Ind., Nov. 8, 2010 EXTENSION, INC . announced ... it will make available for general release to the healthcare ... existing offerings use Cisco IP devices and smartphones as end ... the smartphone devices will not only serve as communication end ...
Cached Medicine Technology:Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 2Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 3Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 4Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 5Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 6Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 7Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 8Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 9EXTENSION, INC. to Launch Apple iPhone Application for Use in Clinical Workflows 2EXTENSION, INC. to Launch Apple iPhone Application for Use in Clinical Workflows 3
(Date:4/17/2014)... PLOS Pathogens , children who live in regions of ... immune response to infection with malaria parasites that may ... and illness and partially control the growth of malaria ... develop future interventions that prevent or mitigate the disease ... 200 million cases of malaria occur worldwide, resulting in ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... a new mechanism that allows blood to enter the ... and the Salk Institute have opened the door to ... damage. , A complex and devastating neurological condition, stroke ... for disability in the U.S. The blood-brain barrier is ... into the brain, causing the permanent deficits in movement ...
(Date:4/17/2014)... potential to ward off depression among retirees, particularly among ... in The Journals of Gerontology, Series B: ... article " Internet Use and Depression Among Retired Older ... the authors report that Internet use reduced the probability ... study sample. , Late-life depression affects between 5 ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... study in the May 1 issue of the journal SLEEP ... sample of exceptionally old adults, including nearly 2,800 people who were ... 65 percent of the sample reported that their sleep quality was ... was about 7.5 hours including naps. Surprisingly, the ...
... ... releases statement on Intellectual Property Day , ... (PRWEB) April 30, 2010 -- Ranjit Shahani, President of the Organization ... the effect drug patent protection is having on innovation in India: , , ,Emotion tends ...
... say C. gattii not infecting as many as ... News) -- The new "killer" fungus spreading through the Pacific ... , "It,s definitely real in that we,ve been seeing this ... lot more meningitis than you would expect in the general ...
... ... designed for any athlete requiring therapy for fatigued or overused shoulder and elbows. ... Dallas, TX (PRWEB) May 2, ... for fatigued or overused shoulder and elbows. This great new product was named Best of ...
... had no adverse effects, researchers say , FRIDAY, April ... and Flumadine appear to be safe for pregnant women ... analyzed the medical records of 239 pregnant women who ... with one of the three drugs. Among these patients, ...
... in running, catching, throwing lead to sedentary lifestyle, study ... than three-quarters of disadvantaged preschool children in the United ... running, jumping, throwing and catching, a new study finds. ... giving up on physical activity and becoming obese teens ...
Cached Medicine News:Health News:Sleeping well at 100 years of age: Study searches for the secrets to healthy longevity 2Health News:Drug Patents in India Helping Promote Innovation 2Health News:Drug Patents in India Helping Promote Innovation 3Health News:'Killer' Fungus Not So Deadly 2Health News:'Killer' Fungus Not So Deadly 3Health News:Chilly-Billy Ice Compress - Arm Care for Athletes 2Health News:Chilly-Billy Ice Compress - Arm Care for Athletes 3Health News:Taking Flu Drugs While Pregnant Appears to Be Safe: Study 2Health News:Motor Skills Lag in Poor Preschoolers 2
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: